News and Announcements
Haatch Ventures exclusive early-stage tech fund now open!
- Published October 17, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Haatch Ventures and their mega-team of multi-exit founders behind the early-stage digital-disruptor investment fund is now raising the 3rd fund of £1.5m+
Launch of their latest fund follows their first two funds, both of which were oversubscribed.
The fund looks for early stage opportunity, but equally, it looks for ideas and founding teams that have the vision and ambitions to deliver that future.
Over the past 6 years under the Haatch Angel brand and the last 18 months under the fund Haatch Ventures, they have been investing in some of the most disruptive global digital companies.
Read below their up to date achievements that they had a chance to present at the recent Wholesale Investor Emergence 2019 event in London by Haatch founder Scott Weavers-Wright
View Emergence presentation here
About Haatch Ventures
EIS fund, Haatch Ventures, enables investors to benefit from our knowledge & experience of investing in disruptive UK technology.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
